Previous 10 | Next 10 |
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q3 2020 Earnings Call Nov 09, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Athersys (ATHX) Q3 2020 Earnings Call Transcript
Athersys, Inc. (ATHX) Q3 2020 Results Earnings Conference Call November 09, 2020, 04:30 PM ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Gil Van Bokkelen - Founder, Chairman and Chief Executive Officer Ivor Macleod - Chief Financial Officer...
Athersys, Inc. (ATHX) Q2 2020 Earnings Conference Call November 09, 2020 4:20 PM ET Company Participants Karen Hunady - Director of Corporate Communications and Investor Relations Ivor Macleod - Chief Financial Officer Gil Van Bokkelen - Chairman and Chief Executive Officer Conference Call Pa...
Athersys (ATHX): Q3 GAAP EPS of -$0.11 misses by $0.01.Revenue of $0.09M misses by $0.16M.Cash and equivalents of $61.7M.Press Release For further details see: Athersys EPS misses by $0.01, misses on revenue
Company announces initiation of MultiStem ® Phase 2 study led by UTHealth in patients with trauma related inflammation and complications at Memorial Hermann-Texas Medical Center Management to host conference call at 4:30 pm EST today Athersys...
Four not-widely-followed biotech stocks were pitched at the recent Ira Sohn conference. Below is the full audio of the pitches, and a list of the publicly-traded landscape for each. For further details see: These Are The Four Biotech Stocks Recently Pitched At The Ira Sohn Conference
SPI Energy (SPI) +56% after launching new EV Company.MediciNova (MNOV) +36% on positive intranasal COVID-19 vaccine data.vTv Therapeutics (VTVT) +20% on positive clinical study results supporting the safety and efficacy of TTP399.Athersys (ATHX) +13% af...
The FDA designates Athersys' (ATHX) MultiStem cell therapy a Regenerative Medicine Advanced Therapy ((RMAT)) for the potential treatment of acute respiratory distress syndrome ((ARDS)).RMAT status includes all the benefits of Fast Track and Breakthrough Therapy, including early interactions w...
ARDS program well-positioned for an expedited path to commercialization with RMAT and Fast Track designation Athersys, Inc., a leading regenerative medicine company in late-stage clinical development, announced today that MultiStem ® cell therapy was granted Reg...
In my last Seeking Alpha article Athersys: Abundance of Opportunity , I gave an overview of the company, highlighted the late-stage programs under development, and offered my views on potential upcoming catalysts. The four months since the publishing of that article has seen an unfortunate ...
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...